BRCA1和STMN1作为接受以顺铂为基础的辅助化疗的非小细胞肺癌患者的预后标志物。
BRCA1 and STMN1 as prognostic markers in NSCLCs who received cisplatin-based adjuvant chemotherapy.
作者信息
Wang Mingxing, Li Wanjun, Xing Xuemei, Zhang Dan, Lei Jie, Li Guoyin
机构信息
Department of Thoracic Surgery, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, China.
Department of Pathology, Hanzhong 3201 Hospital Affiliated to Xi'anJiaotong University, Xi'an, Shaanxi, China.
出版信息
Oncotarget. 2017 Sep 8;8(46):80869-80877. doi: 10.18632/oncotarget.20715. eCollection 2017 Oct 6.
OBJECTIVE
In this study, we aimed to investigate the predictive effect of , , and on the prognosis of patients with non-small cell lung cancer (NSCLC).
METHODS
Seventy NSCLC patients who received platinum-based chemotherapy from June 2009 to July 2011 were enrolled. The protein and mRNA levels of , , and were determined. Survival time of the patients with NSCLC was also calculated.
RESULTS
High expression of or low expression of was associated with a better prognosis in NSCLC patients (<0.01). In contrast, the expression of and were not closely related with the prognosis of NSCLC patients(>0.05). Furthermore, patients with high expression of and low expression of have lived longer (<0.01).
CONCLUSION
and were independently predictors for prognosis of NSCLCs which received cisplatin-based adjuvant chemotherapy.
目的
在本研究中，我们旨在探讨[具体指标1]、[具体指标2]、[具体指标3]和[具体指标4]对非小细胞肺癌（NSCLC）患者预后的预测作用。
方法
纳入2009年6月至2011年7月期间接受铂类化疗的70例NSCLC患者。测定[具体指标1]、[具体指标2]、[具体指标3]和[具体指标4]的蛋白和mRNA水平。计算NSCLC患者的生存时间。
结果
[具体指标1]高表达或[具体指标2]低表达与NSCLC患者较好的预后相关（P<0.01）。相反，[具体指标3]和[具体指标4]的表达与NSCLC患者的预后无密切关系（P>0.05）。此外，[具体指标1]高表达且[具体指标2]低表达的患者生存时间更长（P<0.01）。
结论
[具体指标1]和[具体指标2]是接受顺铂辅助化疗的NSCLC患者预后的独立预测指标。
Zotero 插件